NASDAQ has warned Hancock Jaffe Laboratories (NSDQ:HJLI) that it is in danger of being delisted, but the company said in an SEC filing today that it intends to return to compliance. The warning, issued last week, said Hancock Jaffe did not have the minimum of $2.5 million in stockholders’ equity to merit its listing on the […]
Pavmed (NSDQ:PAVM) said today that it has received formal notice from NASDAQ that it has returned to compliance with the stock exchange’s listing rule after 10 consecutive days with a closing bid price of at least $1 per share. NASDAQ warned the company in November that it was in danger of delisting due to poor […]
Pavmed (NSDQ:PAVM) is in danger of losing its listing on the NASDAQ exchange, according to a report filed with the Securities & Exchange Commission. In August last year, the FDA group reviewing Pavmed’s 510(k) application for its CarpX minimally invasive carpal tunnel release device asked the company to resubmit the application because the group hadn’t reached […]
Invuity (NSDQ:IVTY) said it closed its initial public offering, raising approximately $47.8 million by offering 4.6 million shares at $12 per share. Leerink Partners, Piper Jaffray and Stifel were book-runners for the offering, with William Blair acting as co-manager, the company said. The IPO’s underwriters exercised a 600,000-share over-allotment, the San Francisco, Calif.-based surgical illumination device company […]
Invuity yesterday priced its initial public offering at $12 a share, under the range the advanced surgical lighting maker set earlier in June, looking to raise $48 million. Invuity shares were set to begin trading today under the “IVTY” symbol on the NASDAQ exchange, the company said, but plans for opening have been delayed until […]
Ulthera filed for a U.S. initial public offering yesterday, saying it hopes to raise as much as $86 million when it debuts on the NASDAQ stock exchange.
Mesa, Ariz.-based Ulthera makes an ultrasound device, which is designed to use the body’s natural healing process to non-invasively lift and tighten loose skin on the neck and under the chin.
Vital Therapies priced its initial public offering at $12 per share, once again lowering the bar for its 1st public flotation after scuttling its 1st try at a U.S. IPO.
Vital Therapies, which is developing a bio-artificial liver, last October set the IPO’s price range at $16-$18. But the San Diego-based company but shelved the offering until March, when it set the range at $13-$15 per share.